Suchergebnisse - "Forest, Amelie"

PubPharm (21)

1

Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor

enthalten in: Gan to kagaku ryoho. Cancer & chemotherapy | 2023

von Sato, T. | Forest, A. | Kandaswamy, V. | +2

2

Characterization of 7A5 : A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

enthalten in: Molecular cancer therapeutics | 2020

von Kotanides, H. | Sattler, R. | Lebron, M. | +22

3

Correction to : Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for immunotherapy of cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

ErratumFor: J Immunother Cancer. 2018 Apr 30;6(1):31. - PMID 29712568

4

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for ImmunoTherapy of Cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

5

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for ImmunoTherapy of Cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

6

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for immunotherapy of cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

ErratumIn: J Immunother Cancer. 2018 Jun 4;6(1):45. - PMID 29866166

7

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for ImmunoTherapy of Cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

8

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

enthalten in: Journal for ImmunoTherapy of Cancer | 2018

von Li, Y. | Carpenito, C. | Wang, G. | +18

9

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

enthalten in: Cell reports | 2018

von Schaer, D. | Beckmann, R. | Dempsey, J. | +19

10

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

enthalten in: Molecular cancer therapeutics | 2018

von Bagchi, A. | Haidar, J. | Eastman, S. | +8